Answers are grounded in this paper and cite their sources.
Review examines tumor-associated GPCRs, revealing next-generation strategies to enhance cancer therapies.
G protein-coupled receptors (GPCRs) serve as central hubs in tumor signal transduction and microenvironment regulation. However, their therapeutic exploitation is confounded by a fundamental complexity: GPCR functions are exquisitely context-dependent, varying across cell types and spatial locations within the heterogeneous tumor microenvironment. A single receptor may drive malignant proliferation while simultaneously recruiting immunosuppressive cells, and pathways inhibited by small molecules can be reactivated through parallel axes. This multidimensional regulatory conundrum renders conventional single-axis inhibition strategies inherently limited. This review systematically examines the distribution and pathological functions of tumor-associated GPCRs, critically analyze why current mainstream modalities often fail in the TME context, and spotlight next-generation strategies such as allosteric modulation, targeted protein degradation, nucleic acid therapeutics, and engineered cell therapies that are uniquely poised to actively modulate the TME in a context-aware manner. By integrating enabling technologies including artificial intelligence, cryo-electron microscopy, and organoid models, we chart a transformative path from single-axis inhibition toward multi-dimensional regulation, ultimately advancing more durable cancer therapies.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: